cetrelimab (JNJ-63723283) / Xoma, J&J  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cetrelimab (JNJ-63723283) / J&J
NCT03551782: A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Completed
1b
33
Europe, Canada, US, RoW
Cetrelimab 480 mg, JNJ-63723283, Apalutamide 240 mg, JNJ-56021927
Janssen Research & Development, LLC
Castration-Resistant Prostatic Neoplasms
11/21
11/21
NCT03547037: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Completed
1
22
Japan
JNJ-63723283, Cetrelimab, Erdafitinib
Janssen Pharmaceutical K.K.
Neoplasm
07/22
07/22
NCT05242445: A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Completed
1
11
Europe
Cetrelimab, JNJ-63723283, Placebo
Janssen Research & Development, LLC
Hepatitis B, Chronic
05/23
05/23
NCT06311578: A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Recruiting
1
66
US
JNJ-87704916, Cetrelimab, JNJ-63723283
Johnson & Johnson Enterprise Innovation Inc.
Advanced Solid Tumors
11/28
11/33
NCT05818683: A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

Recruiting
1
345
US, RoW
JNJ-78278343, Cetrelimab, JNJ-63723283, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP)
Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Neoplasms
06/25
09/27
NCT06116786: A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Recruiting
1
76
Europe, US, RoW
JNJ-86974680, Cetrelimab, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Non-small-Cell Lung
04/27
07/28

Download Options